TNXP vs CBIO

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Sep 09, 2026

TNXP

38.5
AI Score
VS
TNXP Wins

CBIO

36.1
AI Score

Investment Advisor Scores

TNXP

39score
Recommendation
SELL

CBIO

36score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric TNXP CBIO Winner
Revenue 20.42M 1.04M TNXP
Net Income -80.75M -48.12M CBIO
Net Margin -395.4% -4631.4% TNXP
Operating Income -84.07M -51.09M CBIO
ROE -36.3% -29.5% CBIO
ROA -31.8% -26.3% CBIO
Total Assets 254.09M 182.76M TNXP
Cash 176.23M 171.59M TNXP
Current Ratio 6.61 9.66 CBIO
Free Cash Flow -86.84M -28.56M CBIO

Relative Price Performance (Last 90 Days)

TNXP 1M: -0.8% · 3M: +11.5% CBIO 1M: +18.1% · 3M: +5.8%

Current Technical Phase

TNXP

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 40

RSI (14): 40.1 · Price: $11.87

CBIO

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (0.8% over 20 days), RSI 58

RSI (14): 58.0 · Price: $19.41

Fundamentals Snapshot

Metric TNXP CBIO
Market Cap
Forward P/E -1.5 -7.4
Trailing P/E
Revenue (TTM)
Revenue Growth 5.8% 0.0%
Gross Margin 0.8% 1.0%
Operating Margin -3.1% -14.3%
EPS -12.53 -0.14
Dividend Yield

Frequently Asked Questions

Based on our detailed analysis, TNXP is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.